Triera Biosciences

Unlocking the Power of Aptamers to Deliver Targeted Treatments

Triera Biosciences is pioneering a transformative aptamer platform with breakthrough potential for development of new treatments. Preclinical trials have demonstrated efficacy that have matched or exceeded monoclonal antibodies.

What if we could develop treatments faster, more economically, and more effectively?

The global health picture in the 21st century clearly illustrates the need for new dynamic health solutions. Global pandemics, evolving viruses, and an increasing senior population worldwide demand a faster and more effective approach.

Triera Biosciences is demonstrating the incredible potential of aptamers to create treatment platforms that are equal parts groundbreaking, effective, and accessible.